Advertisement

Topics

Tyrogenex Completes Patient Enrollment in its Phase 2 Trial of Orally Administered Vorolanib for Wet Age-related Macular Degeneration

08:30 EST 9 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Tyrogenex, a privately held biopharmaceutical company, today announced the completion of patient enrollment in the APEX Study – a phase 2 trial of X-82 (vorolanib) for the oral treatment of wet age-related macular degen...

Other Sources for this Article

Company Contact:
Tyrogenex Corporate Communications
Kirsten Hollis, 301-880-9595
info@tyrogenex.com
or
Media Contact:
MacDougall Biomedical Communications
Kara Mazey, 781-235-3060
kmazey@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "Tyrogenex Completes Patient Enrollment in its Phase 2 Trial of Orally Administered Vorolanib for Wet Age-related Macular Degeneration"

Advertisement
Quick Search
Advertisement
Advertisement